Pharmanovia — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $200M

Overview

Pharmanovia is a private, commercial-stage pharmaceutical company that has built a significant global presence by focusing on the life cycle management of established small molecule drugs. Its business model centers on acquiring or licensing mature pharmaceutical brands and then leveraging patient insights to repurpose, reformulate, or re-engineer them to address ongoing unmet needs, thereby extending their commercial viability. With a portfolio of over 25 brands, operations in 15+ offices, and a team of 320+ employees, the company positions itself as an agile and imaginative partner for innovator pharma companies seeking to maximize the potential of their mature assets. The recent appointment of a new CEO with extensive multinational pharma experience signals a phase of strategic growth and consolidation.

CardiovascularEndocrinologyNeurologyOncology

Technology Platform

Specialized expertise in pharmaceutical life cycle management (LCM), utilizing patient insights to re-engineer, repurpose, and re-commercialize established off-patent drugs.

Funding History

1

Total raised:$200M

Debt$200MBlackRockMay 15, 2022

Opportunities

The large and growing universe of off-patent drugs divested by big pharma provides a steady stream of acquisition targets.

There is significant opportunity to add value through geographic expansion into underserved markets and through life cycle management strategies like reformulation and repurposing, which address ongoing unmet patient needs at a lower cost than novel drug development.

Risk Factors

Revenue is reliant on a concentrated portfolio of mature products vulnerable to generic competition and pricing pressures.

The business model depends on successfully executing complex life cycle management projects and integrating acquisitions, with failure risking sunk costs.

Global supply chain complexity for numerous products introduces operational and quality risks.

Competitive Landscape

Pharmanovia competes with other specialty pharma and generic companies that focus on acquiring mature brands, such as STADA, Viatris, and numerous private equity-backed firms. Its differentiation lies in its focused life cycle management expertise and patient-insight-driven approach to re-innovation, rather than purely generic commercialization. It also competes with originator companies that retain and manage their own mature brands.

More companies in United Kingdom →